FindTrial
Sign In

The optimal dose of daunorubicin in induction therapy for newly diagnosed acute myeloid leukemia

The optimal dose of daunorubicin in induction therapy for newly diagnosed acute myeloid leukemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029563
Enrollment
Unknown
Registered
2020-02-04
Start date
2017-01-05
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

escalated-dose group:patients administrated with daunorubicin 75mg/m2 (D1-3)
Standard-dose group:patients administrated with daunorubicin 60mg/m2 (D1-3)

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. A definite diagnosis of AML was made in accordance with World Health Organization (WHO) criteria combined with clinical manifestations, morphological, immunophenotypic and cytogenetic analysis; 2. Patients without receiving any treatment before; 3. Patients aged 15–60 years.

Exclusion criteria

Exclusion criteria: 1. AML-M3 patients; 2. Secondary AMLs; 3. The patient has serious complications and can't tolerate the chemotherapy,such as serious infection , severe renal or/and cardiac or/and liver insufficiency; 4. After signing the consent, the patient and the agent request to withdraw from the clinical study.

Design outcomes

Primary

MeasureTime frame
complete remission;complete remission CR without minimal residual disease;—

Secondary

MeasureTime frame
Overall survival;Refactory free survival ;—

Countries

China

Contacts

Public ContactYong-Qian Jia

West China Hospital, Sichuan University

Jia_yq@scu.edu.cn+86 18980601198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026